Your Recent Quotes: 0 | 0

Vertex Pharmaceuticals Incorporated

Related Information and Financials
Price Glossary Definition
25.44 -0.62
-2.38%
10/10/08 4:00
Open
24.58
Prev Close
26.06
Volume
4,488,442
52 Wk. Range
13.84-37.23
Year-to-Date Performance Glossary Definition
UP  9.51%
Latest Dividend
Dividend
N/A
Yield
N/A
Ex-Date
N/A
Price/Earnings Comparisons Glossary Definition
 
-8.96
 
0.00
 
13.50
VRTX
Sect. Av.
S&P 500
Market Cap
3,780,867,400
Outstanding Shares
140,356,000
TheStreet Rating Glossary Definition
  • A
  • B
  • C
  • D
  • E
Buy VRTX Rating Report
Target Price (1Yr)
High
50.00
Revenue
207,800,000

Annual Dividend
Rate
0.00
Yield
0.00
Growth
12 Month
3 Year
CAGR
Revenue
-8.00
0.94
0.24
Net Income
1.35
0.00
EPS
0.43
0.00

Stock Performance History
 
3 Month
1 Year
3 Year
Price Change
-24.06
-30.01
19.49
Earnings Per Share($)

12/2005
 
 
 
-2.28
12/2006
 
 
 
-1.84
12/2007
 
 
 
-3.03

Earnings
EBITDA
-385,214,000
Revenue
199,012,000
Outside Analyst Rating History

10/12/08
9
Buy
10/12/08
6
Hold
10/12/08
0
Sell

Jim Cramer Portfolio
Find out now if VRTX is in Jim's personal portfolio at Action Alerts PLUS.
Compare This Stock
Latest Headlines
The Nasdaq and Amex biotechnology indices are up 1.2% and 0.7%, respectively.

6:26PM 09/24/08

Vertex shares fell Monday after the pharmaceutical company expanded its stock sale.

4:22PM 09/22/08

Vertex initially falls hard on a stock-sale plan but rallies late in the day with the broader market.

6:40PM 09/18/08

See who made what calls.

8:45PM 09/02/08

Shares were jumping more than 7% after being beaten down by concerns about diabetes drug Byetta.

10:19AM 08/28/08

The Market Vectors Environmental Industry ETF gets a buy rating.

9:33AM 08/22/08

The medical device maker rose on an earnings beat.

4:12PM 08/19/08

The drugmakers reached a deal with U.S. and European regulators to start the new phase II study for the hepatitis treatment.

8:33PM 08/18/08

The company was the best performer on the Amex Pharmaceuticals Index Friday.

5:26PM 08/15/08

Drug company says "no" to Roche's advances, says make a better offer worth considering.

5:16PM 08/13/08

Understanding the Market

Our Experts' Take at RealMoney
Here's what our writers like in this market.

3:00PM 10/10/08

I'm working on new downside targets in a revisit to my Dow 8400 scenario.

5:25AM 10/10/08

More Experts' Takes


Premium Stock Ideas
Is Cramer trading VRTX in his Action Alerts Plus Portfolio?